TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02111993

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Defibrillation Testing
Description: Once the ICD is implanted, Standard Defibrillation Threshold (DFT) testing will begin. A low energy shock will be delivered to the heart at the peak of the T wave to induce ventricular fibrillation (VF). Once VF is induced, a rescue shock of 25J will be delivered to restore sinus rhythm. This process will be repeated once more after 5 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Limit of Vulnerability Testing
Description: Once the ICD is implanted, Upper Limit of Vulnerability (ULV) testing will commence. An 18 J shock will be delivered will at different points from the t-wave. If VF is not induced with any of these shocks, then the ULV will be considered to be 18J. If VF is induced, then a 25 J rescue shock will be delivered.
Study: NCT02326779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
Study: NCT00581295

Intervention type: DEVICE
Intervention: Diffuse optical spectroscopy
Description: Diffuse optical spectroscopy measurment
Study: NCT04009044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afimoxifene
Description: Apply topically

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Biopsy
Description: Undergo core needle biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01609842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifaceted Intervention with pharmacist and IVR
Description: An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.

Intervention type: OTHER
Group type: OTHER
Intervention: Multifaceted Intervention with pharmacist and IVR
Description: An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
Study: NCT03671031

Intervention type: PROCEDURE
Intervention: isolated roux loop
Description: Isolated roux loop reconstruction following pancreaticoduodenectomy

Intervention type: PROCEDURE
Intervention: single loop
Description: Conventional single loop reconstruction following pancreaticoduodenectomy
Study: NCT01218607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: Treatment will be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken twice daily for 16 weeks
Study: NCT03984305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal KinetiGraph® (PKG®) Watch
Description: The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~* A wrist-worn data logger (PKG Watch) designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~* An application to configure the data logger and transfer the acquired data at the end of a recording.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Personal KinetiGraph® (PKG®) Watch
Description: The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~* A wrist-worn data logger (PKG Watch) designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~* An application to configure the data logger and transfer the acquired data at the end of a recording.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal KinetiGraph® (PKG®) Report
Description: The Personal KinetiGraph (PKG®) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by GKC.~The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~• A series of algorithms that analyze the uploaded data, producing a PDF that is delivered to the clinician. The PDF contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility.
Study: NCT04451629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvıc base exercıse, core exercise
Description: Effectıveness of the pelvıc base exercıse on the paın and qualıty of lıfe ın dysmenoral youth 40 minutes exercise intervention 4 times a week for 8 weeks
Study: NCT03017053

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy after primary surgery in the treatment of early oral cancer based on adverse pathological factor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective neck dissection
Description: Elective neck dissection after primary surgery in the treatment of early oral cancer based on adverse pathological factor
Study: NCT03076983

Intervention type: DEVICE
Intervention: Lung Monitoring with EIT device (PulmoVista 500)
Description: Patient's lungs will be monitored during clinical routine interventions with Dräger's EIT device (PulmoVista 500).~No medical interventions to routine patient care required.

Intervention type: DEVICE
Intervention: Lung Monitoring with EIT device (PulmoVista 500)
Description: Patient's lungs will be monitored during clinical routine interventions with Dräger's EIT device (PulmoVista 500).~No medical interventions to routine patient care required.
Study: NCT02979431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171 3.0 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171 6.0 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171 9.0 mg/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04094220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral lumbar interbody fusion
Description: LLIF is an indirect decompression technique, and does not directly remove the disc or osteophyte protruding into the spinal canal. Its decompression effect is not as thorough as traditional posterior decompression surgery. Usually, posterior decompression is required for patients who have unsuccessful indirect decompression.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral lumbar interbody fusion
Description: LLIF is an indirect decompression technique, and does not directly remove the disc or osteophyte protruding into the spinal canal. Its decompression effect is not as thorough as traditional posterior decompression surgery. Usually, posterior decompression is required for patients who have unsuccessful indirect decompression.
Study: NCT00796315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxylamine Succinate USP
Description: One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL
Study: NCT00194545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication diaries
Description: Caregivers expected to complete medication diaries daily
Study: NCT02693587

Intervention type: DRUG
Intervention: Misodel and Angusta

Intervention type: DRUG
Intervention: Misodel and Angusta
Study: NCT02889432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Melatonin 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02249910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration of 5 mg daily for one week, then escalated to 10 mg daily for one week, followed by escalation to 20 mg daily for 41 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Oral administration of 850 mg twice daily for 3 days followed by 850 mg on day 4, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-\[8-(2-hydroxybenzoyl) amino\] caprylate) and 3) co-administration with oral semaglutide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: Oral administration of 0.5 mg single dose, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-\[8-(2-hydroxybenzoyl) amino\] caprylate) and 3) co-administration with oral semaglutide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral administration of SNAC 300 mg. Will be administered with the morning dose of metformin (1st, 3rd, 5th and 7th dose). On Day 24, a single SNAC dose will be administered with digoxin.
Study: NCT04378608

Intervention type: DRUG
Group type: OTHER
Intervention: OBV/PTV/r) ± ribavirin (RBV)
Study: NCT04313907

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: low level laser therapy plus topical clonazepam
Description: combination of treatment, low level laser therapy (15 joules, 6 sesions, 14 days) plus topical clonazepam (1 mg,3 times per day, 14 days)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham laser plus topical clonazepam
Description: Sham laser therapy (0 joules, 6 sesions, 14 days) plus topical clonazepam(1 mg,3 times per day, 14 days)

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Active laser plus placebo of topical clonazepam
Description: low level laser therapy (15 joules, 6 sesions, 14 days) plus placebo topical clonazepam(lactose,3 times per day, 14 days)
Study: NCT02303626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02596412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: use the module with augmented reality (Mini-Docs) on tablet during TB injection
Description: Provision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology
Study: NCT04744337

Intervention type: PROCEDURE
Group type: OTHER
Intervention: orthodontic treatment
Description: fixed orthodontic treatment in adolescent females initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion.
Study: NCT02004873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micra Pacemaker Implant
Study: NCT03814980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindful breathing application
Description: Participants will use a mindful breathing application on a computer tablet.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: application on a computer tablet
Description: a computer tablet
Study: NCT02538068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Surveys
Description: Participants complete 28 daily surveys of daily meaning, mood, and physical activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Random Surveys (8)
Description: Participants complete 8 random surveys of activities over the past 24 hours during the first 4 weeks.
Study: NCT01337076

Intervention type: DEVICE
Group type: OTHER
Intervention: cochlear implant
Description: Cochlear implant surgery
Study: NCT00927836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride solution
Description: Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
Study: NCT02313779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lovingkindness Meditation (LKM)
Description: Compassionate behavior training (REVISE)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lovingkindness Meditation (LKM)
Description: Compassionate behavior training (REVISE)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lovingkindness Meditation (LKM)
Description: Compassionate behavior training (REVISE)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness Meditation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness Meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Study: NCT01861405

Intervention type: BEHAVIORAL
Intervention: neuropsychological testing and quality of life assessments

Intervention type: BEHAVIORAL
Intervention: neuropsychological testing and quality of life assessments

Intervention type: RADIATION
Intervention: Standard of Care WBRT or SRS

Intervention type: DEVICE
Intervention: Functional magnetic resonance imaging

Intervention type: DEVICE
Intervention: Functional magnetic resonance imaging
Study: NCT03099707

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Ambassador
Description: This multi-component intervention, titled the Treatment Ambassador Program, will target people living with HIV who have not initiated ART within 3 months of testing positive. Our intervention will last for 8 sessions over 8-14 weeks, and will aim to address the three steams of influences on decision-making through a system of patient navigation and support with an assigned partner living with HIV who is trained in motivational interviewing. It will be aimed at addressing barriers to ART initiation identified through our prior qualitative research, as framed through the Theory of Triadic Influence, by addressing the three streams of influences on decision-making through a system of patient navigation and support.
Study: NCT01532531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEMORE Multi-Function Electrotherapy Stimulator
Description: The Collateral Meridian Therapy (CMT) group patients received, according to the CMT protocol described previously (5), CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study.
Study: NCT03167073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BreastFeeding Friend (BFF)
Description: A novel android app designed to improve breastfeeding rates among low-income women

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dummy app
Description: A novel android app that looks identical to the intervention app (BFF) but contains limited content.
Study: NCT03959722

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ecologic® PERFORMANCE
Description: Ecologic® PERFORMANCE is a probiotic formulation consisting of different probiotic bacterial strains, namely:~Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Enterococcus faecium W54 Lactobacillus acidophilus W22 Lactobacillus brevis W63 Lactococcus lactis W58~Except for the bacterial strains, Ecologic® PERFORMANCE contains the following other ingredients:~* maize starch and maltodextrins~* fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~* vegetable protein~* mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains no bacterial strains, but the following ingredients:~* maize starch and maltodextrins~* fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~* vegetable protein~* mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)
Study: NCT00132067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study: NCT00044512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
Study: NCT02673645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAGA Innovations
Description: An intensive math tutoring program.
Study: NCT04455529

Intervention type: OTHER
Intervention: ESUS
Description: Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism.
Study: NCT02851004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Napabucasin
Description: 1 cycle is 21days.~BBI608: Oral administration at a dose of 240mg or 480 mg twice daily (BID), every day.~\[Additional cohort to the Phase II part\] Oral administration at a dose of 240mg mg BID, every day~The therapy will be repeated until meeting the discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 1 cycle is 21days.~Pembrolizumab: Administration at a dose of 200 mg/body on Day 1 of each cycle~\[Additional cohort to the Phase II part\] Administration at a dose of 200 mg/body on Day 1 of each cycle.~The therapy will be repeated until meeting the discontinuation criteria.
Study: NCT01962051

Intervention type: DEVICE
Intervention: Amplatzer Cardiac Plug
Study: NCT00268242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: 10 mg/m2/ min IV for 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: 12 mg/m2/day IV (administer over 30-60 minutes) on Day 1, 2 and 3
Study: NCT02841969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrolysed water
Description: Irrigation of wound using electrolysed water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prontosan
Description: Irrigation of wound using Prontosan
Study: NCT01394588

Intervention type: DEVICE
Intervention: Use of continuous glucose monitor during surgery. ( Medtronic Minimed Guardian REALTime Continuous Glucose Monitor)
Description: Use of continuous glucose monitor during surgery.
Study: NCT02799680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic CART-33
Description: allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
Study: NCT00630955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: Memantine 20 mg once per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine 40 mg once per day for 7 days
Study: NCT04887142

Intervention type: OTHER
Intervention: Standard of health care
Description: The patients in this observational study will be exposed to the standard health care interventions according to the hospital diagnostic and treatment protocols and procedures and clinical judgment of the treating physicians.

Intervention type: OTHER
Intervention: Standard of health care
Description: The patients in this observational study will be exposed to the standard health care interventions according to the hospital diagnostic and treatment protocols and procedures and clinical judgment of the treating physicians.
Study: NCT00630955

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once per day for 7 days
Study: NCT00756873

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of placebo
Description: Placebo qd orally day 0-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of etoricoxib
Description: Etoricoxib 90 mg qd orally day 0-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of etoricoxib
Description: Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
Study: NCT02948621

Intervention type: PROCEDURE
Intervention: Endoscopic sleeve gastroplasty
Description: Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
Study: NCT01730235

Intervention type: OTHER
Intervention: MyMediHealth access
Description: Patients who will be given access to a web-based medication scheduling and SMS-based reminder system.
Study: NCT01816581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Targin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxynorm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study: NCT02133989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticlopidine + Ginko biloba
Description: ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel bisulfate 97.875mg(75mg as clopidogrel)
Study: NCT03462407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DAID
Description: The DAID intervention group will engage in imitation based dog training, using positive reinforcement training (operant conditioning) to teach their dog to copy the physical actions they demonstrate on the command Do it.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dog walking
Description: Children will participate in dog walking. Trained assistants will teach the children to teach their dog basic commands. Dog walking will occur during the intervention phase and children will be encourage to walk their dogs at home.
Study: NCT03268915

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3 minutes sit-to-stand test
Description: 3 minutes sit-to-stand test, 1 minute sit-to-stand test, 6 minutes walk test will be performed 2 times for each patients 3 minutes sit-to-stand test with oxygen uptake measurement will be performed one time for each patient
Study: NCT02483312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12
Study: NCT04427631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone conduction headphones
Description: Children will be offered hearing support with bone conduction headphones that can either be paired to a microphone or to a tablet/ phone/ computer to help children to hear. The Hear Glue Ear app is available for free to provide speech and language enrichment.
Study: NCT00671255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once daily for up to 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.
Study: NCT00722150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: 2 mg/kg/day x 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: 4 mg/kg/day x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: 6 mg/kg/day x 7 days